Enriqueta Felip
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 411 publications
DESTINY-Lung06: trastuzumab deruxtecan and pembrolizumab as first-line treatment for HER2-overexpressing, PD-L1 TPS <50% NSCLC.
Journal: Future oncology (London, England)
Published: September 02, 2026
SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 27, 2026
Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 26, 2026
Quality and safety of research biopsies in oncology clinical trials.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 21, 2026
Lorlatinib in patients with ALK-positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study.
Journal: Future oncology (London, England)
Published: April 08, 2026
Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 07, 2026
A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.
Journal: Future oncology (London, England)
Published: March 30, 2026
MiracleNet: A Biologically Interpretable Machine Learning Model for Resected Non-small-cell Lung Cancer.
Journal: Computational and structural biotechnology journal
Published: March 21, 2026
Patient-reported outcomes with adagrasib in KRYSTAL-12.
Journal: Lancet (London, England)
Published: March 13, 2026
First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 01, 2026
Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.
Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 29, 2026
Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer: Insights From the EVOKE-01 Study.
Journal: Cancer research communications
Published: January 22, 2026
Last Updated: 09/26/2026